FGF23 and Phosphate–Cardiovascular Toxins in CKD
Elevated levels of fibroblast growth factor 23 (FGF23) and phosphate are highly associated with increased cardiovascular disease and mortality in patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the secretion o...
Main Authors: | Isabel Vogt, Maren Leifheit-Nestler |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/11/11/647 |
Similar Items
-
FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
by: Robert Stöhr, et al.
Published: (2018-06-01) -
Corrigendum: FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
by: Robert Stöhr, et al.
Published: (2018-07-01) -
Paracrine Effects of FGF23 on the Heart
by: Maren Leifheit-Nestler, et al.
Published: (2018-05-01) -
Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
by: Merita Rroji, et al.
Published: (2020-02-01) -
Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy
by: Fiona Eitner, et al.
Published: (2022-01-01)